Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.85B |
| 2 |
Tesla
TSLA
|
+$1.78B |
| 3 |
Apple
AAPL
|
+$1.57B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$1.49B |
| 5 |
Mastercard
MA
|
+$1.09B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$1.3B |
| 2 |
Phillips 66
PSX
|
+$650M |
| 3 |
iShares China Large-Cap ETF
FXI
|
+$475M |
| 4 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$432M |
| 5 |
NRG Energy
NRG
|
+$387M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.59% |
| 2 | Financials | 9.21% |
| 3 | Consumer Discretionary | 7.33% |
| 4 | Healthcare | 5.59% |
| 5 | Communication Services | 5.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SNCR
4376
DELISTED
Synchronoss Technologies
SNCR
| $72.7K | ﹤0.01% |
6,676
-8,050
| -55% | -$79.8K |
|
4377
Sunoco
SUN
$14.4B
| $72.6K | ﹤0.01% |
1,251
-464,768
| -100% | -$26.3M |
|
4378
Zura Bio
ZURA
$516M
| $71.9K | ﹤0.01% |
55,759
-22,764
| -29% | -$35.9K |
|
4379
Biomea Fusion
BMEA
$84.6M
| $71.8K | ﹤0.01% |
33,688
-13,216
| -28% | -$45K |
|
|
CLYM
4380
Climb Bio
CLYM
$681M
| $71.7K | ﹤0.01% |
58,730
+8,926
| +18% | +$14.5K |
|
4381
Kaspi.kz JSC
KSPI
$16.9B
| $71.6K | ﹤0.01% |
+771
| New | +$75.6K |
|
4382
Vor Biopharma
VOR
$1.15B
| $71.6K | ﹤0.01% |
4,987
+4,436
| +805% | +$107K |
|
|
DAWN
4383
CALL
DELISTED
Day One Biopharmaceuticals
DAWN
| $71.4K | ﹤0.01% |
9,000
| – | – |
|
|
DAWN
4384
PUT
DELISTED
Day One Biopharmaceuticals
DAWN
| $71.4K | ﹤0.01% |
9,000
| – | – |
|
4385
Vanguard Morningstar Value ETF
VTV
$188B
| $71.2K | ﹤0.01% |
412
| – | – |
|
4386
HireQuest
HQI
$180M
| $70.6K | ﹤0.01% |
5,932
-2,719
| -31% | -$36.7K |
|
|
VTYX
4387
DELISTED
Ventyx Biosciences
VTYX
| $70.6K | ﹤0.01% |
61,363
-30,306
| -33% | -$52K |
|
4388
Innovator US Equity Power Buffer ETF September
PSEP
$846M
| $70.4K | ﹤0.01% |
1,833
-1,943
| -51% | -$76.3K |
|
4389
Similarweb
SMWB
$628M
| $69.8K | ﹤0.01% |
8,438
-2,508
| -23% | -$30.9K |
|
4390
VEON
VEON
$3.62B
| $69.8K | ﹤0.01% |
1,600
| – | – |
|
4391
Genasys
GNSS
$76.1M
| $69.6K | ﹤0.01% |
30,662
-30,452
| -50% | -$84.4K |
|
4392
DiaMedica Therapeutics
DMAC
$342M
| $69.2K | ﹤0.01% |
18,270
-9,456
| -34% | -$54.1K |
|
|
RHLD
4393
Resolute Holdings Management
RHLD
$1.02B
| $69K | ﹤0.01% |
+2,203
| New | +$78.1K |
|
|
FINV
4394
FinVolution Group
FINV
$1.15B
| $68.7K | ﹤0.01% |
7,137
| – | – |
|
4395
Invivyd
IVVD
$158M
| $68.5K | ﹤0.01% |
113,115
-14,065
| -11% | -$12.6K |
|
|
ARTV
4396
Artiva Biotherapeutics
ARTV
$491M
| $68.3K | ﹤0.01% |
22,753
-1,408
| -6% | -$7.6K |
|
4397
Lexicon Pharmaceuticals
LXRX
$1.03B
| $67.3K | ﹤0.01% |
146,071
-97,245
| -40% | -$61.4K |
|
4398
FT Vest US Equity Buffer ETF September
FSEP
$1.22B
| $66.9K | ﹤0.01% |
1,502
-1,736
| -54% | -$79.7K |
|
|
FSFG
4399
DELISTED
First Savings Financial Group
FSFG
| $66.7K | ﹤0.01% |
2,590
-207
| -7% | -$5.19K |
|
|
FRGE
4400
DELISTED
Forge Global Holdings
FRGE
| $66.5K | ﹤0.01% |
7,891
-3,794
| -32% | -$43.8K |
|
Similar funds
Barclays's Q1 2025 Portfolio in Review
As of Q1 2025, Barclays held 5,710 positions worth $353B, down 1.2% from $357B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Barclays deployed $16.5B of net new capital in Q1 2025, opening 439 new positions and adding to 1,449 existing holdings. Its largest new stake was JPMorgan BetaBuilders USD High Yield Corporate Bond ETF: 318,453 shares worth $14.7M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 18% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Honeywell, an estimated $1.3B trimmed.
- Barclays's largest Q1 2025 buy was JPMorgan BetaBuilders USD High Yield Corporate Bond ETF: 318,453 shares worth $14.7M.
- Barclays added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $3.85B increase.
- Barclays's biggest Q1 2025 reduction was Honeywell, cutting an estimated $1.3B.
- Barclays fully exited Smartsheet Inc. in Q1 2025, selling an estimated $45.7M.
- Barclays's ten largest holdings make up 37% of its $353B portfolio in Q1 2025.
- Barclays opened 439 new positions and closed 470 in Q1 2025.
- Barclays's portfolio value fell 1.2% quarter-over-quarter to $353B.
Based on Barclays's 13F filing for Q1 2025, filed 15 May 2025.